1. Home /
    2. Altai Protocol Library /
  2. New Drug: Dostarlimab for advanced dMMR endometrial cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Drug: Dostarlimab for advanced dMMR endometrial cancer

New Drug: Dostarlimab for advanced dMMR endometrial cancer
Study:
  • Open-label phase I study (GARNET)
  • Recurrent or advanced endometrial cancer that progressed on/after platinum-based regimen
  • Dostarlimab in MMR deficient (dMMR, n = 103) and MMR proficient (MMRp, n = 142)
Efficacy:
  • CR: 11% vs. 3%
  • ORR: 46% vs. 19%
  • 18mo DoR rate: 79.2% vs. 61.3%
Safety:
  • Grade >=3 AEs: anemia (12%), abdominal pain (5%), dyspnea (4%)

Annals of Oncology (2020) 31 (suppl_4): S1142-S1215.

Oaknin A, et al. Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET

https://doi.org/10.1016/annonc/annonc325

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More